Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. - Wikidata - awgldk - TriplyDB

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

http://www.wikidata.org/entity/Q42536013

about

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.Acute inducible ablation of GRP78 reveals its role in hematopoietic stem cell survival, lymphogenesis and regulation of stress signaling.Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.Prostate cancer as a model for tumour immunotherapy.New insights into androgenic immune regulation Update on prostate cancer vaccines Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions T cells localized to the androgen-deprived prostate are TH1 and TH17 biased.Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.Immunotherapy for prostate cancer: an emerging treatment modality.Current status of immunological therapies for prostate cancer.Recent advances in immunotherapy for the treatment of prostate cancer.Current status of immunological approaches for the treatment of prostate cancer Optimal therapy sequencing in metastatic castration-resistant prostate cancer.PROSTVAC® targeted immunotherapy candidate for prostate cancer.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.Androgen regulation of host defenses and response to inflammatory stimuli in the prostate gland.Immune Therapy for Prostate Cancer.Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes.Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer.The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis.Androgen depletion augments antibacterial prostate host defences in rats.Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.Sipuleucel-T and immunotherapy in the treatment of prostate cancer.Androgen-Induced Immunosuppression.Androgen deprivation and immunotherapy for the treatment of prostate cancer

P2860

Q26851608-B64033C9-D47B-4715-9E2E-07E12E523D31 Q33606027-09A4D73A-A9FA-44FF-98D0-CACDE1D8AF55 Q33621393-5F130F2A-5B00-426F-9066-E2A00F39CD80 Q33798326-CF3FD30D-767B-49D7-98C7-9FECDB60EE66 Q33872776-1A43736D-2B33-420D-B455-058710EBD367 Q34314109-B552DE51-BCCA-476D-B16C-86BDE4BFEC0F Q34321844-F44DA04B-3B3D-4300-8300-4D5319960A02 Q34856875-8539BCB0-F304-431C-9C09-D6F653FF7CFB Q34936575-1E3D49AC-BF24-405A-8F40-2BE5545FE54E Q36169608-BB2E2CF2-ED78-4317-B56E-7A5B60763E2D Q36316871-32034417-CE55-4012-8573-FF8FBC90DCCB Q36708792-43267662-82D9-4976-8F00-5155C0ACDF10 Q36760953-103D7130-0514-4CA0-A2CB-B2076F744C9A Q36905460-E8615DCD-B62A-4A55-82C4-D3EF923229FB Q37676065-877D7DFE-F093-4C78-B6D4-862A2BD0CBAA Q37691634-171C1D2B-4B5E-4A6B-9B10-F94BFBC5AFA3 Q37697477-F770E1ED-23FE-421B-AB42-F7BFE1E638DF Q37889984-12249A4C-D1C4-4E58-891E-CCD3D4E2F9FE Q37983491-77EAAC05-885E-4483-BEF6-948C4F0A73F0 Q38097373-E1A6B7C7-B40E-4BEE-8BEA-3E9E01D9E974 Q38206815-4CB696D4-D33D-4F90-8B07-A819D017CB79 Q38600417-7ECA6759-6C1E-4489-B28C-9707C562CE2C Q38780080-B1B8E45F-A9CF-43C4-8722-3F32EC516ED9 Q38937569-394342C7-8E12-44DD-93F2-1C81D36BDA93 Q38982667-8F7C7CCD-CADA-4102-B091-4D5B1DF59151 Q39249471-7A1B2625-0A68-4C50-96C3-8D9481F615DF Q39473961-BC952D3B-EC36-4E0F-9135-EA3D69537824 Q39666393-26109089-8CCB-459F-9B7B-3E9B81716DEB Q41161352-93B3C8AC-6D07-4223-BF4F-D4A66FBB1F83 Q42265633-8CFCF485-9772-49BB-A89D-DC0D2CFE2942 Q42925679-84AB3207-F62E-4497-B4A9-A28DDFC10FC1 Q43117942-1D24ABC6-9970-4B47-9993-1C96103D10A2 Q43725536-2F319B8E-28A4-4E9B-83E9-82FBB9B612B4 Q47603855-9239FD92-9632-428A-AD96-1CBF12809C98 Q47757361-E81A2E2A-7879-4989-AFFF-D951E0FA1335 Q53062915-5F0259BB-8496-4B4E-BF64-F639A712106F Q55357541-0A8DE3DE-F598-4124-8045-923771F1CAE6 Q57115565-D3FFFA28-6627-4C9F-B75D-67E894A06ED7

P2860

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

http://www.wikidata.org/entity/Q42536013

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Androgen ablation augments pro ...... en applied after immunization.

@en

Androgen ablation augments pro ...... en applied after immunization.

@nl

type

label

Androgen ablation augments pro ...... en applied after immunization.

@en

Androgen ablation augments pro ...... en applied after immunization.

@nl

prefLabel

Androgen ablation augments pro ...... en applied after immunization.

@en

Androgen ablation augments pro ...... en applied after immunization.

@nl

P1433

Q42536013-7BD6BDDD-989E-4131-84E7-8D14A94DF199

P1476

Q42536013-9617023B-A1E3-4CE8-9F7F-8E9965EB5708

P2093

Q42536013-0739BFF1-F245-423D-AE9A-92D37FC71C3E

Q42536013-70369337-8033-4657-939E-765CD76838FE

Q42536013-B445365E-2DB3-4CA0-B5BA-34D03E5BD448

Q42536013-BC8729A7-B34B-4B31-BC98-31D3AEEEA1E9

Q42536013-F2868B26-8735-48FF-9AAE-78558497FC21

P2860

Q42536013-003E1671-7C7A-4B05-A374-529BCBEC2D68

Q42536013-0FCB330F-E0A1-4851-B1F1-30C6BCD2B8B8

Q42536013-14722B79-EB5C-4E0B-888F-34395A20022C

Q42536013-1EB27237-14CB-407A-AFB7-BE137CB7EA3D

Q42536013-24F69DCE-EDEB-4619-859A-17BBC4059E5F

Q42536013-2FE8C9C2-A348-4835-B6D5-9D984D818319

Q42536013-352D59DE-231D-4338-889E-D945DE270F59

Q42536013-39E32F10-E598-44A2-AF42-FDDC263DF635

Q42536013-3B1A901A-FFD9-4E8B-8720-BFC76613F4AA

Q42536013-45A2CA3A-38C6-42F7-B23A-ABBC94E36BCF

P304

Q42536013-01CAF69A-39C3-42E4-BA19-937211897933

P31

Q42536013-4C18A393-7DF4-4E1F-AC22-C4AFB14DF11C

P356

Q42536013-BB5F2FE3-7A76-463C-AF1F-4F2F9519DA99

P433

Q42536013-82882965-6F8D-4256-99AC-8E6C47B365FD

P478

Q42536013-DA2DA532-BC80-4993-8694-61EC90BDF8B0

P577

Q42536013-353F681C-BCB6-48FC-8F55-DDDD4ABBB3A5

P5875

Q42536013-89FC54C7-41DC-4E0B-B3D8-CE0E397CBC0F

P698

Q42536013-7C84641D-BA0B-45E5-A67A-FA2B94E25A8A

P921

Q42536013-886D4225-CCAE-4A4C-B5E0-FFE30EABF464

P932

Q42536013-37C7F979-0FF7-4C03-AAB2-B6EE658954D7

P356

P1433

P1476

Androgen ablation augments pro ...... en applied after immunization.

@en

P2093

Andrew Gray

http://www.w3.org/2001/XMLSchema#string

Bolyn Hubby

http://www.w3.org/2001/XMLSchema#string

Sean A Higgins

http://www.w3.org/2001/XMLSchema#string

W Martin Kast

http://www.w3.org/2001/XMLSchema#string

Yi T Koh

http://www.w3.org/2001/XMLSchema#string

P2860

Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate

Analysis of the multiple interactions between IL-12 and the high affinity IL-12 receptor complex

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

The dendritic cell system and its role in immunogenicity

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.

P304

571-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.20906

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23786487

http://www.w3.org/2001/XMLSchema#string

P698

19143030

http://www.w3.org/2001/XMLSchema#string

P921

P932

2732563

http://www.w3.org/2001/XMLSchema#string